158 related articles for article (PubMed ID: 31126772)
1. Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression.
Di Maida F; Mari A; Scalici Gesolfo C; Cangemi A; Allegro R; Sforza S; Cocci A; Tellini R; Masieri L; Russo A; Carini M; Minervini A; Serretta V
Clin Genitourin Cancer; 2019 Aug; 17(4):e751-e758. PubMed ID: 31126772
[TBL] [Abstract][Full Text] [Related]
2. Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer.
Soria F; Moschini M; Abufaraj M; Wirth GJ; Foerster B; Gust KM; Özsoy M; Briganti A; Gontero P; Mathieu R; Rouprêt M; Karakiewicz PI; Shariat SF
Urol Oncol; 2017 Mar; 35(3):113.e9-113.e14. PubMed ID: 27908681
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.
Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF
Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906
[TBL] [Abstract][Full Text] [Related]
4. The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial.
Elsawy AA; El-Assmy AM; Bazeed MA; Ali-El-Dein B
Urol Oncol; 2019 Mar; 37(3):179.e9-179.e18. PubMed ID: 30448030
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Intravesical Doxorubicin Immediately Following Resection of Primary Non-muscle-invasive Bladder Cancer: A Propensity Score-matched Analysis.
Fukuokaya W; Kimura T; Miki J; Kimura S; Watanabe H; Bo F; Okada D; Aikawa K; Ochi A; Suzuki K; Shiga N; Abe H; Egawa S
Clin Genitourin Cancer; 2020 Apr; 18(2):e55-e61. PubMed ID: 31630978
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer.
Kimura S; Soria F; D'Andrea D; Foerster B; Abufaraj M; Vartolomei MD; Karakiewicz PI; Mathieu R; Moschini M; Rink M; Egawa S; Shariat SF; Gust KM
Clin Genitourin Cancer; 2018 Dec; 16(6):e1123-e1132. PubMed ID: 30061034
[TBL] [Abstract][Full Text] [Related]
7. Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer.
Lian F; Chen W; Liu Y; Shen L; Fan W; Cui W; Zhao Y; Li J; Wang Y
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1625-1633. PubMed ID: 30900154
[TBL] [Abstract][Full Text] [Related]
8. Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
Bosschieter J; Nieuwenhuijzen JA; van Ginkel T; Vis AN; Witte B; Newling D; Beckers GMA; van Moorselaar RJA
Eur Urol; 2018 Feb; 73(2):226-232. PubMed ID: 28705539
[TBL] [Abstract][Full Text] [Related]
9. Continuous saline bladder irrigation after blue light transurethral resection of bladder tumor increases recurrence-free survival in low- to intermediate-risk non-muscle invasive bladder cancer.
Gondran-Tellier B; Abdallah R; Sichez PC; Akiki A; Toledano H; Gaillet S; Delaporte V; Karsenty G; Bastide C; Daniel L; Garcia S; Rossi D; Lechevallier E; Boissier R; Baboudjian M
Prog Urol; 2021 May; 31(6):316-323. PubMed ID: 33663939
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer.
Abdelrahman AE; Rashed HE; Elkady E; Elsebai EA; El-Azony A; Matar I
Ann Diagn Pathol; 2019 Apr; 39():42-52. PubMed ID: 30684846
[TBL] [Abstract][Full Text] [Related]
11. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review.
Perlis N; Zlotta AR; Beyene J; Finelli A; Fleshner NE; Kulkarni GS
Eur Urol; 2013 Sep; 64(3):421-30. PubMed ID: 23830475
[TBL] [Abstract][Full Text] [Related]
12. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.
Vartolomei MD; Ferro M; Cantiello F; Lucarelli G; Di Stasi S; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdona S; Verze P; La Rocca R; Borghesi M; Schiavina R; Brunocilla E; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Battaglia M; Serretta V; Russo GI; Morgia G; Terracciano D; Musi G; de Cobelli O; Mirone V; Shariat SF
Clin Genitourin Cancer; 2018 Dec; 16(6):445-452. PubMed ID: 30077463
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor expression as a predictor of chemotherapeutic resistance in muscle-invasive bladder cancer.
Mansour AM; Abdelrahim M; Laymon M; Elsherbeeny M; Sultan M; Shokeir A; Mosbah A; Abol-Enein H; Awadalla A; Cho E; Sairam V; Park TD; Shahid M; Kim J
BMC Urol; 2018 Nov; 18(1):100. PubMed ID: 30413194
[TBL] [Abstract][Full Text] [Related]
14. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
[TBL] [Abstract][Full Text] [Related]
15. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.
Kim WT; Kim J; Yan C; Jeong P; Choi SY; Lee OJ; Chae YB; Yun SJ; Lee SC; Kim WJ
Ann Oncol; 2014 May; 25(5):974-9. PubMed ID: 24631944
[TBL] [Abstract][Full Text] [Related]
16. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
17. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
[TBL] [Abstract][Full Text] [Related]
18. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
19. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
[No Abstract] [Full Text] [Related]
20. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
